New Horizons: Finally, Approaches to Treating Moderate-to-Severe Atopic Dermatitis and Implications for Asthma

Allergy/ Immunology
Curriculum:
A Self-Assessment Program on Managing Atopic Dermatitis​ and Improving Patient Outcomes
Credits:
1.25 AMA PRA Category 1 Credit(s)™
Launch Date:
25-Apr-17
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians, nurse practitioners, and physician assistants who specialize in allergy/immunology and dermatology

Relevant Terms:

Atopic Dermatitis (AD)

Bradley E. Chipps, MD

Bradley E. Chipps, MD
Medical Director, Respiratory Therapy and the Cystic Fibrosis Center
Sutter Medical Center
Capital Allergy and Respiratory Disease Center
Sacramento, CA

Bradley E. Chipps, MD, received his medical degree from the University of Texas Medical Branch, Galveston, Texas. He was a pediatric resident for 2 years before serving in the Air Force at Ellsworth Air Force Base in South Dakota for 2 years as a general pediatrician. He then completed a combined allergy and pulmonary fellowship at Johns Hopkins University, Baltimore, Maryland, and spent 1 year on the faculty in the Pediatric Respiratory Sciences Division.

Dr Chipps has been in private practice in Sacramento, California, since 1979. He is the medical director of Respiratory Therapy and the Cystic Fibrosis Center at Sutter Medical Center in Sacramento and is also the associate medical director of the Sutter Community Hospitals Sleep Laboratory, which he established in 1984. He is board certified in pediatric pulmonology and allergy and clinical immunology. Dr Chipps is also president-elect of the American College of Allergy, Asthma and Immunology (ACAAI).

Mark Boguniewicz, MD

Mark Boguniewicz, MD
Professor, Division of Allergy-Immunology, Department of Pediatrics
National Jewish Health and University of Colorado School of Medicine
Denver, CO

Mark Boguniewicz, MD, completed his residency in pediatrics at Children's Hospital of Michigan, Detroit, Michigan, and a fellowship in allergy-immunology and rheumatology at Children's Hospital and Harvard Medical School in Boston, Massachusetts. He is board certified in pediatrics and allergy-immunology.

Dr Boguniewicz is professor in the Division of Allergy-Immunology, Department of Pediatrics, at National Jewish Health and University of Colorado School of Medicine in Denver, Colorado. He is a fellow of the American Academy of Allergy, Asthma, and Immunology (AAAAI), past chair of the Dermatologic and Ocular Diseases Interest Section, and past chair of the Eczema Committee. He is also a fellow of the American College of Allergy, Asthma and Immunology (ACAAI). He is on the editorial board of Journal of Allergy and Clinical Immunology: In Practice. He served on the Joint Task Force on Topical Calcineurin Inhibitors of the AAAAI and ACAAI, and he was co-chair of the treatment section of the European Academy of Allergology and Clinical Immunology/AAAAI/PRACTALL Consensus Group for atopic dermatitis. He has served on the Joint Task Force of the AAAAI/ACAAI for the 2004 and 2012 Practice Parameter for Atopic Dermatitis.

Dr Boguniewicz's research focuses on immunopathogenesis and new treatments for atopic dermatitis. He is an investigator in the National Institutes of Health Atopic Dermatitis Research Network. He has lectured at many national and international meetings, and he has published more than 300 peer-reviewed articles, reviews, chapters and abstracts. He is the recipient of the 1998–1999, 2010–2011, 2011–2012, and 2012–2013 Pediatric Allergy-Immunology Fellows Outstanding Teacher Award, the 2002 Faculty Clinician of the Year Award, and the 2006 AAAAI's Richard S. Farr Memorial Lectureship. He has been selected for Best Doctors in America from 2003 through 2016. He is also the recipient of the 2013 AAAAI Distinguished Clinician Award.

Jonathan Silverberg, MD, PhD, MPH

Jonathan Silverberg, MD, PhD, MPH
Assistant Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine
Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Jonathan Silverberg, MD, PhD, MPH, is an assistant professor in the Departments of Dermatology, Preventive Medicine, and Medical Social Sciences at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr Silverberg is the director of the Northwestern Medicine Multidisciplinary Eczema Center and founded the Multidisciplinary Eczema Clinic at Northwestern Medicine. He is also the director of the contact dermatitis clinic and photobiologic testing at Northwestern Memorial Hospital, which provides comprehensive evaluation and management of skin allergies and photosensitivity. He was the recipient of the Georg Rajka Medal from the International Society of Atopic Dermatitis, the Teacher of the Year Award in the Department of Dermatology at Northwestern Memorial Hospital, and the Everett C. Fox Research Award from the American Academy of Dermatology.

Dr Silverberg completed both his medical degree and master of public health degree in 2009 at State University of New York, Downstate Medical Center in Brooklyn, New York. His master's thesis focused on the protective role of herpesviridae on atopic dermatitis and other allergic disorders as part of the broader "hygiene hypothesis." He completed his doctorate in 2006 with thesis studies in neuroimmunology focused on murine immune responses after a seizure. He performed his residency training at St. Luke's-Roosevelt Hospital Center at Columbia University in New York City, New York.

His research goals are to better understand the risk factors and medical comorbidities of atopic dermatitis in the U.S. population. Dr Silverberg has authored 141 scientific articles and book chapters, including studies of the epidemiology of atopic dermatitis and "big data" research. He has extensive experience with database development, instrument development and deployment, and statistical programming.

Dr Silverberg is an associate editor for the British Journal of Dermatology and Current Dermatology Reports and is on the editorial board of Cutis. He is a member of the National Eczema Association Scientific Advisory Committee and American Academy of Dermatology Atopic Dermatitis Expert Resource Group, and he is chair of the Society of Investigative Dermatology Atopic Dermatitis Epidemiology Working Group. He is also a member of the Alpha Omega Alpha honor society, American Academy of Dermatology, Society of Investigative Dermatology, American Contact Dermatitis Society, Illinois Dermatologic Society, and Chicago Dermatologic Society.

Linda Stein Gold, MD

Linda Stein Gold, MD
Director, Dermatology Clinical Research
Division Head, Dermatology
Henry Ford Health System
Detroit, MI

Linda Stein Gold, MD, earned her undergraduate degree at the Wharton School of the University of Pennsylvania in Philadelphia, Pennsylvania, and her medical degree at the University of Pennsylvania School of Medicine. She completed her residency in dermatology at Henry Ford Hospital in Detroit, Michigan.

Dr Stein Gold is director of Dermatology Clinical Research at Henry Ford Health System in Detroit, Michigan, as well as division head of Dermatology at Henry Ford Health System in West Bloomfield, Michigan.

Dr Stein Gold is active in clinical research on a variety of dermatologic conditions, including the treatment of chronic plaque-type psoriasis, actinic keratosis, atopic dermatitis, acne vulgaris, seborrheic dermatitis, and rosacea. She has published articles in journals such as the Journal of the American Academy of Dermatology, Cutis, and the Journal of Drugs in Dermatology, among others. She is a frequent national and international lecturer on acne, rosacea, psoriasis, actinic keratosis, alopecia, viral infections, atopic dermatitis, and fungal infections at grand rounds and medical society meetings. She has been on the medical board of the National Acne and Rosacea Society and the National Psoriasis Foundation medical board. She is a member of the board of directors of the American Academy of Dermatology.
1. Describe the pathogenesis of atopic dermatitis (AD) and the "atopic march" and discuss how the underlying pathology of the disease can be used to direct therapy
2. Utilize current therapies and describe how to utilize emerging treatments for AD based on safety and efficacy data, pathophysiology, guidelines, individual patient needs, and sustained efficacy, especially in patients with moderate-to-severe AD
3. Manage quality-of-life issues, psychosocial comorbidities, and treatment-related anxiety in patients with AD
4. Engage the patient as a partner in his or her care plan to ensure best treatment adherence and outcomes

Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Bradley E. Chipps, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Genentech, Meda, Merck, and Novartis (Consulting Fees).​
  • Mark Boguniewicz, MD, has affiliations with Celgene and Regeneron (Consulting Fees); and Anacor (Research Grants).
  • Jonathan Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anacor, Eli Lilly, GlaxoSmithKline (GSK), MedImmune, Procter & Gamble, Pfizer, PuriCore, and Regeneron-Sanofi (Consulting Fees); and AbbVie, Celgene, Eli Lilly, GSK, Regeneron-Sanofi, and Roche (Investigator in Clinical Trials).
  • Linda Stein Gold, MD, has affiliations with Allergan, Celgene, Galderma, Leo, Medimetriks, Novartis, Otsuka, Pfizer, and Valeant (Consulting Fees); Allergan, Celgene, Galderma, GSK, Leo, Novartis, and Valeant (Contracted Research); and Allergan, Celgene, Galderma, Leo, Medimetriks, Novartis, and Valeant (Fees for Non-CME/CE Services); and Roche (Medical/Legal Consulting).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
 
RMEI Medical Education, LLC
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Chelsey Goins, PhD, has no affiliations with commercial interests to disclose.
  • Elizabeth Paczolt, MD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests to disclose.
Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
 
Media
Internet
 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 
Fee Information
There is no fee for this educational activity.
 
Statement of Commercial Support
This activity is jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an independent medical educational grant from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals.
 
How to Receive Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.25 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
 
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.